Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | CTSD | P07339 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329658 | 0.85 | TSHR (0.62) | ALDH1A1TSHRMEN1KMT2ACTSL | |
| SCHEMBL1328433 | 0.85 | CTSD (0.54) | ALDH1A1TSHRMEN1KMT2ACTSL | |
| SCHEMBL4472678 | 0.84 | TSHR (0.60) | ALDH1A1TSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13627741 | 0.83 | GLA (0.54) | ALDH1A1TSHRL3MBTL1GLAHTT | |
| SCHEMBL25313503 | 0.83 | ALDH1A1 (0.59) | ALDH1A1TSHRMEN1KMT2AUSP2 | |
| SCHEMBL5445038 | 0.83 | ALDH1A1 (0.59) | ALDH1A1TSHRMEN1KMT2ACTSL | |
| SCHEMBL28018778 | 0.83 | MEN1 (0.59) | ALDH1A1TSHRMEN1KMT2ACTSL | |
| SCHEMBL9354347 | 0.82 | SIGMAR1 (0.56) | ALDH1A1TSHRMEN1KMT2ACTSL | |
| SCHEMBL19820853 | 0.82 | KMT2A (0.50) | ALDH1A1TSHRMEN1KMT2ACTSL | |
| SCHEMBL9358258 | 0.81 | GLA (0.54) | ALDH1A1MEN1KMT2ACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504653-A | Carboxylic acid amidation method | 国网安徽省电力有限公司电力科学研究院 | 2025-02-25 | — | — | CN | disclosed |
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9630931-B2 | Pharmaceutically active pyrazine derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2017-04-25 | — | — | US | disclosed |
| EP-2780331-B1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | SENTINEL ONCOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2780331-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | Sentinel Oncology Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072502-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | SENTINEL ONCOLOGY LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
| EP-1495009-B1 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1495009-B1 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-12 | — | — | EP | disclosed |
| US-6878706-B1 | Cyanamides useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1495009-A2 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086325-A2 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086325-A2 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323484-A1 | Pharmaceutically Active Pyrazine Derivatives | PHKG1, PHKG2, PLK2 | ALDH1A1 3558/4885TSHR 2138/4885MEN1 2168/4885 |
| US-20170247341-A1 | PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES | PHKG1, PHKG2, PEAK1 | ALDH1A1 3827/4885TSHR 2077/4885MEN1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.